Home

Biomaterials Translational ›› 2022, Vol. 3 ›› Issue (1): 31-54.doi: 10.12336/biomatertransl.2022.01.005

• REVIEW • Previous Articles     Next Articles

The long and winding road: homeostatic and disordered haematopoietic microenvironmental niches: a narrative review

Suzanne M. Watt1,2,3,*()   

  1. 1 Stem Cell Research, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
    2 Myeloma Research Laboratory, Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia
    3 Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia
  • Received:2021-12-01 Revised:2022-03-05 Accepted:2022-03-10 Online:2022-03-28 Published:2022-03-28
  • Contact: Suzanne M. Watt E-mail:suzanne.watt@ndcls.ox.ac.uk;suzanne.watt@adelaide.edu.au
  • About author:Suzanne M. Watt., suzanne.watt@ndcls.ox.ac.uk or suzanne.watt@adelaide.edu.au.

Abstract:

Haematopoietic microenvironmental niches have been described as the ‘gatekeepers’ for the blood and immune systems. These niches change during ontogeny, with the bone marrow becoming the predominant site of haematopoiesis in post-natal life under steady state conditions. To determine the structure and function of different haematopoietic microenvironmental niches, it is essential to clearly define specific haematopoietic stem and progenitor cell subsets during ontogeny and to understand their temporal appearance and anatomical positioning. A variety of haematopoietic and non-haematopoietic cells contribute to haematopoietic stem and progenitor cell niches. The latter is reported to include endothelial cells and mesenchymal stromal cells (MSCs), skeletal stem cells and/or C-X-C motif chemokine ligand 12-abundant-reticular cell populations, which form crucial components of these microenvironments under homeostatic conditions. Dysregulation or deterioration of such cells contributes to significant clinical disorders and diseases worldwide and is associated with the ageing process. A critical appraisal of these issues and of the roles of MSC/C-X-C motif chemokine ligand 12-abundant-reticular cells and the more recently identified skeletal stem cell subsets in bone marrow haematopoietic niche function under homeostatic conditions and during ageing will form the basis of this research review. In the context of haematopoiesis, clinical translation will deal with lessons learned from the vast experience garnered from the development and use of MSC therapies to treat graft versus host disease in the context of allogeneic haematopoietic transplants, the recent application of these MSC therapies to treating emerging and severe coronavirus disease 2019 (COVID-19) infections, and, given that skeletal stem cell ageing is one proposed driver for haematopoietic ageing, the potential contributions of these stem cells to haematopoiesis in healthy bone marrow and the benefits and challenges of using this knowledge for rejuvenating the age-compromised bone marrow haematopoietic niches and restoring haematopoiesis.

Key words: ageing, COVID-19, GvHD, haematopoietic stem cell niche, mesenchymal stromal cells, rejuvenating niche, skeletal stem cells